An overview of product candidates in clinical trials and the more than 30 life science companies developing novel therapies for Alzheimer’s disease
Rethinking Immunotherapy for Brain Tumors
February 22, 2012 By Leave a Comment
Eight companies with immunotherapy approaches for brain tumors
Three Late-Stage Leukemia Company Previews for ASCO
May 8, 2011 By 1 Comment
Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
Similarities Between Two Immunotherapies in Cancer
March 30, 2011 By 1 Comment
Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Follow MD Becker Partners